Skip to main content

Holiday schedule

Our Patient Service Centers will be closed on Monday, May 26, 2025 for the Memorial Day Holiday. Have a healthy, happy holiday.

Hide
Quest Diagnostics

mGen

Detect Mgen with the FDA-cleared Aptima® Assay

Find the hidden STI that might be harming your patients.

Mycoplasma genitalium, or Mgen, is a bacterium that can cause cervicitis, pelvic inflammatory disease (PID), and male urethritis. It can coexist with other STIs and cause similar symptoms.
couple reviewing paperwork

Advanced testing amplifies awareness

Recently developed detection capabilities have increased awareness of Mgen as a common STI, prevalent in 10.2% of females and 10.6% of males.1,*

Patients with Mgen can be asymptomatic or can exhibit symptoms that are similar to (or coexist with) other common STIs, including chlamydia, gonorrhea, and/or trichomoniasis.
*Study population included symptomatic and asymptomatic subjects for both sexes.

Mgen can be harmful if left untreated

Detected in up to 30% of women with clinical cervicitis2
  • Identified in up to 22% of PID cases2
  • Infected patients are 2 times more likely to acquire HIV3
Responsible for 30% of persistent or recurrent urethritis in men4

Additionally, Mgen coinfection is common in men

  • C trachomatis: 35%5
  • N gonorrhoeae: 14%5
  • C trachomatis and N gonorrheae: 19%5

With 1 test, diagnose the cause of your patient's symptoms and reduce risks of untreated infection.

  • Frequent urination
  • Abnormal vaginal or penile discharge
  • Vaginal irritation or itching
  • Pain during intercourse
  • Burning during urination
  • Abnormal vaginal bleeding between periods or after intercourse

  • Chlamydia
  • Gonorrhea
  • Trichomoniasis
  • Mgen

STI panels test for all 4 pathogens with 1 urogenital samplea

aSTI panels can be performed with any of the collection devices shown above.


Mgen can be highly resistant to first-line antibiotics; alternate treatment may be necessary to avoid serious complications.

Although STIs present with similar symptoms, each responds better to different medications. Mgen can be highly resistant to standard first-line antibiotics, in which case, other medications may be necessary to avoid serious complications.


Get the answers you and your patients need with 1 test from Quest

FDA-cleared Aptima Assay from Quest uses nucleic acid amplification testing (NAAT), the preferred method of detection per the CDC.6

Test name Test code
SureSwab®, Mycoplasma genitalium only, Real-Time PCR 91475
Sexually Transmitted Infections (STIs) Cervicitis Panel
Included tests:
Chlamydia/Neisseria gonorrhoeae RNA, TMA, Urogenital
SureSwab, Trichomonas vaginalis RNA, Qualitative, TMA
Mycoplasma genitalium, rRNA, TMA		 36962
Sexually Transmitted Infections (STIs) Pelvic Inflammatory Disease (PID) Panel
Included tests:
Chlamydia/Neisseria gonorrhoeae RNA, TMA, Urogenital
SureSwab, Trichomonas vaginalis RNA, Qualitative, TMA
Mycoplasma genitalium, rRNA, TMA		 36965
Sexually Transmitted Infections (STIs) Male Urethritis Panel
Included tests:
Chlamydia/Neisseria gonorrhoeae RNA, TMA, Urogenital
Trichomonas vaginalis RNA, Qualitative, TMA, MalesMycoplasma genitalium, rRNA, TMA		 36964
Sexually Transmitted Infections (STIs) Male Urethritis Panel Expanded
Included tests:
Chlamydia/Neisseria gonorrhoeae RNA, TMA, Urogenital
Trichomonas vaginalis RNA, Qualitative, TMA, Males
Mycoplasma genitalium, rRNA, TMA
SureSwab, Ureaplasma species, Real-Time PCR		 38288
All components of panels can be ordered separately: Chlamydia trachomatis RNA, TMA, Urogenital (test code 11361); Neisseria gonorrhoeae (test code 11362); Chlamydia/Neisseria gonorrhoeae RNA, TMA, Urogenital (test code 11363); SureSwab Trichomoniasis RNA, Qualitative, TMA (test code 19550); SureSwab Ureaplasma species Real-Time PCR (test code 91476); Trichomonas vaginalis RNA, Qualitative, TMA, Males (test code 90801); Mycoplasma genitalium, rRNA, TMA (test code 91475).
Visit the Test Directory to order the right test for your patients today

Test codes may vary by location. Please contact your local laboratory for more information.

 

​References:

  1. Gaydos CA, Manhart LE, Taylor SN, et al. Molecular testing for Mycoplasma Genitalium in the United States: Results from the Ames Prospective Multicenter Clinical Study. J Clin Microbial. 2019;57(11). doi:10.1128/jcm.01125-19
  2. CDC. Sexually Transmitted Infections Treatment Guidelines, 2021. Mycoplasma genitalium. Published July 22, 2021. Accessed September 13, 2021. https://www.cdc.gov/std/treatment-guidelines/mycoplasmagenitalium.htm
  3. Napierala Mavedzenge S, Weiss HA. Association of Mycoplasma genitalium and HIV infection: a systematic review and meta-analysis. AIDS. 2009;23(5):611-620. doi:10.1097/QAD.0b013e328323da3e
  4. Ronda J, Gaydos CA, Perin J, et al Does the Sex Risk Quiz predict Mycoplasma genitalium infection in urban adolescents and young adult women? Sex Transm Dis. 2018;45(11):728-734.doi:10.1097/OLQ
  5. Mena, L., Wang, X., Mroczkowski, T. F., & Martin, D. H. (2002). Mycoplasma genitaliuminfections in asymptomatic men and men with urethritis attending a sexually transmitted diseases clinic in New Orleans. Clin Infect Dis, 35(10), 1167–1173. https://doi.org/10.1086/343829
  6. Workowski KA. Bolan GA. CDC. Sexually transmitted diseases treatment guidelines. 2015. published correction appears in MMWR Recomm Rep. 2015;64(33):9241. MMWR Recomm Rep. 2015;64(RR-03):1-137
Universal screening with opt-out for CT/NG screening

The latest CDC Guidelines recommended considering universal screening with opt-out as part of routine care for all female patients ages 15 - 24.*
*Workowski KA, et al. MMWR. doi:10.15585/mmwr.rr7004a1

Click to learn more

Assessing high-risk patients

With rates of sexually transmitted infections (STIs) on the rise, assessing women who may be high-risk is more important than ever.

Click to learn more

STI webinar series

Listen to the experts as they discuss STI testing beyond Chlamydia trachomatis and Neisseria gonorrheae.

Click to learn more

Contact us

Contact us to receive additional information on our lab tests, services, and coverage

Contact us

Symptomatic Testing

Test directory

With more than 3,500+ tests available, we can support every stage of a woman’s life with important insights

Learn more

Resources

We offer a variety of useful resources for healthcare professionals

View Resources

Patient info

For assistance with questions about the testing process or locations, call 1.866.MYQUEST (1.866.697.8378)

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.